ActHIB Vaccine
Regulated Product — Business License RequiredB2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.
Product Overview
ActHIB Vaccine is a Haemophilus influenzae type b (Hib) conjugate vaccine. Its labelling describes it for the prevention of invasive disease caused by Haemophilus influenzae type b, given as a four-dose series and described for use in infants and children from 2 months through 5 years of age.
Product Information
The following description reflects information associated with the Haemophilus influenzae type b conjugate vaccine and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.
Described Uses
- Described for active immunisation to help prevent invasive disease caused by Haemophilus influenzae type b
- Described for infants and children from 2 months through 5 years of age
- Described as given as a four-dose series on the schedule set by the healthcare provider
Described Dosage & Administration
- Administered only by a healthcare professional as an intramuscular injection — not self-administered
- Given as a four-dose series; the dose timing and duration set by the doctor should be followed
- All doses in the schedule should be completed for the vaccine to work as intended
Described Side Effects
Commonly described side effects of Hib conjugate vaccines include:
- Injection-site reactions (pain, redness, swelling)
- Fever
- Irritability
- Loss of appetite and drowsiness
These are described as usually short-lived. Any severe, persistent, or unexpected reaction requires prompt medical attention.
Precautions
- Full medical records should be shared with the healthcare team to avoid inappropriate combination with other products
- Any previous allergic reaction to a vaccine or vaccine component should be disclosed before administration
- Administration may be delayed during an acute febrile illness, per manufacturer guidance
- For an older recipient who is pregnant or breastfeeding, this should be discussed with the doctor beforehand
This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.
B2B, Import & Export Enquiries
SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.
We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.
Request Product Information
Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.
Frequently Asked Questions
Per its labelling it is a Haemophilus influenzae type b (Hib) conjugate vaccine given for active immunisation to help prevent invasive Hib disease, described as a four-dose series in infants and children from 2 months through 5 years of age. SDO Pharma has not independently verified the manufacturer’s claims and does not claim any specific regulatory approval unless independently confirmed.
Its labelling states it is administered by a healthcare professional as an intramuscular injection, on the four-dose schedule set by the doctor. All doses should be completed as advised.
Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.
Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.
Related Product Categories
SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.